Skip to main content

antibodies Archives

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


Autoimmunity advance

Aug. 24, 2021—Vanderbilt researchers have developed a high-throughput screening method to identify and characterize antigen-specific B cells — potential biomarkers for autoimmune disease and targets for new treatments.

Read more


Shared antibodies may push COVID-19 variants: VUMC study

Aug. 10, 2021—Researchers at Vanderbilt University Medical Center have found that people recovering from COVID-19 and those vaccinated against the causative virus, SARS-CoV-2, produce identical clones, or groups, of antibody-producing white blood cells.

Read more


Chikungunya antibody identified at VUMC moves forward

Mar. 4, 2021—Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Read more


COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials

Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Read more


Study finds COVID-19 antibodies drop substantially in the weeks following infection

Sep. 17, 2020—The antibody levels to SAR-CoV-2, the virus that causes COVID-19, substantially drop in the weeks following infection, according to a study led by Vanderbilt University Medical Center and the Centers for Disease Control and Prevention (CDC).

Read more


Study identifies antibodies that block alphaviruses

Aug. 20, 2020—Researchers at Vanderbilt University Medical Center have identified antibodies that, in animals, block infection by alphaviruses, which can cause chronic and debilitating joint pain and arthritis and are an increasing global health concern.

Read more


Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19

Jul. 15, 2020—Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

Read more


Antibodies eye Pacific Island “fever”

May. 14, 2020—Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

Read more


HIV/AIDS expert Nabel set for next Discovery Lecture

Nov. 6, 2019—Gary Nabel, MD, PhD, Chief Scientific Officer and Senior Vice President of Sanofi, will deliver the next Flexner Discovery Lecture on Thursday, Nov. 14.

Read more


New method tested to block chikungunya infection

Jun. 14, 2019—Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more